ReShape Lifesciences Surges 25132.5% in Trading Volume Ranking 329th with $265 Million Turnover

On June 12, 2025, ReShape Lifesciences (RSLS) saw a significant surge in trading volume, with a total turnover of $265 million, marking a 25132.5% increase from the previous day. This substantial rise placed ReShape among the top performers in the stock market, ranking 329th in terms of trading volume for the day. The stock price of ReShape Lifesciences (RSLS) rose by 35.81%.

ReShape Lifesciences has secured an exclusive distribution partnership with Recon Supply, granting access to approximately 18 million potential patients through Recon Supply's established network within the Veterans Administration (VA) and Department of Defense (DoD) healthcare systems. This partnership allows Recon Supply to distribute ReShape's full product line, including the FDA-cleared STIMEL-03 neuromuscular rehabilitation device, the next-generation Lap-Band® 2.0 FLEX, and other ReShape products.

The agreement facilitates access to ReShape's FDA-cleared medical technologies specifically for veterans and military personnel recovering from various conditions. This strategic partnership is expected to expand access to proven, life-changing treatments for a significant number of U.S. veterans and active military personnel. The Lap-Band® 2.0 FLEX, a next-generation, minimally invasive weight loss solution, offers a safe and adjustable option for individuals struggling with obesity.

ReShape Lifesciences has access to VA and DoD facilities through various contracts, including the Distribution and Pricing Agreement, Federal Supply Schedule, and Electronic Catalog contracts. This collaboration underscores ReShape's commitment to delivering high-impact, clinically proven solutions to patients in need, particularly those who have served the country.